Showing 4401-4410 of 5627 results for "".
- Bio-Techne and Narayana Nethralaya Collaborate On the Use of Ella for Ophthalmic Disorder Diagnostic Applicationshttps://modernod.com/news/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications/2479224/Bio-Techne announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella. The Ella platform, which is currently sold for research use only, allows users to perform high-qualit
- Three Companies Combine to Form Corza Medicalhttps://modernod.com/news/three-companies-combine-to-form-corza-medical/2479217/Corza Medical, a provider of surgical products and technologies, was formed after uniting Surgical Specialties Corporation, Caliber Ophthalmics, and the TachoSil hemostatic patch device. &
- Biogen’s Phase 2/3 Gene Therapy Study for XLRP Fails to Meet Primary Endpointhttps://modernod.com/news/biogens-phase-2-3-gene-therapy-study-for-xlrp-fails-to-meet-primary-endpoint/2479216/Biogen announced topline results from the phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP). The XIRIUS study did not meet its primary endpoint of demonstrating a st
- EyeTech Digital Systems Releases the EyeOn Open Eye-Tracking Platformhttps://modernod.com/news/eyetech-digital-systems-releases-the-eyeon-open-eye-tracking-platform/2479214/EyeTech Digital Systems announced the release of its software ecosystem for the EyeOn family of eye-tracking tablets. Software-agnostic EyeOn devices support EyeTech’s applications as well as third-party applications, arming engineers and end users with the highest reliability and lowest in
- GenSight Biologics Provides 2021 Operations Update in the Context of COVID-19https://modernod.com/news/gensight-biologics-provides-2021-operations-update-in-the-context-of-covid-19/2479212/GenSight Biologics provided an update on the impact of COVID-19 on its operations in 2021. “It has been slightly over a year since we had to adjust our operations to the COVID-19 situation and provided you with an update on our activities. Although conditions have improved in many regions,
- Arctic Vision Announces Exclusive Licensing Agreement With ActualEyeshttps://modernod.com/news/arctic-vision-announces-exclusive-licensing-agreement-with-actualeyes/2479210/Arctic Vision and ActualEyes, a clinical stage Japanese biotech company committed to the research and development of cell therapy for corneal endothelial diseases, jointly announced an exclusive licensing agreement for Arctic Vision to develop and commercialize ActualEyes’ lead product cand
- At-Home App Helps Patients Stay Engaged and Adherent to Vision Monitoring Remotelyhttps://modernod.com/news/at-home-app-helps-patients-stay-engaged-and-adherent-to-vision-monitoring-remotely/2479208/Novartis announced it has begun a US pilot program for OdySight, a clinically tested mobile application designed to help monitor vision remotely. Recent changes to public health protocols, paired with a growing patient population and existing treatment burden, have placed an emphasis on vi
- First Pediatric Patient with Rare Genetic Eye Disease Dosed in Clinical Trialhttps://modernod.com/news/first-pediatric-patient-with-rare-genetic-eye-disease-dosed-in-clinical-trial/2479207/ProQR Therapeutics has announced the first pediatric clinical trial participant has been treated in its new clinical trial named Brighten of the experimental RNA therapy sepofarsen. Brighten is a clinical study for children under 8 years old with Leber congenital amaurosis (LCA) d
- Modernizing Medicine Releases Enhanced Ophthalmic Image Management to Improve Clinical Workflowhttps://modernod.com/news/modernizing-medicine-releases-enhanced-ophthalmic-image-management-to-improve-clinical-workflow/2479198/Modernizing Medicine announced it has released the latest version of ophthalmic Image Management aimed at helping ophthalmologists save time and deliver efficiency associated with diagnostic imaging workflows. Many ophthalmologists benefit from having an all-in-one solution that bridges da
- RVL Pharmaceuticals Upneeq Wins 2021 MedTech Breakthrough Awardhttps://modernod.com/news/rvl-pharmaceuticals-upneeq-wins-2021-medtech-breakthrough-award/2479196/RVL Pharmaceuticals, a subsidiary of Osmotica Pharmaceuticals, announced that its ptosis drug Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of the “Best New Technology Solution for Drug Delivery” award in the fifth annual MedTech Breakthrough Award